Shire exercises option on adenosine A2A antagonist candidate for CNS
This article was originally published in Scrip
Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Under the agreement Heptares has granted Shire an exclusive licence to worldwide development and commercial rights to A2A antagonists discovered by Heptares. Heptares receives an upfront option fee and is also eligible to receive milestone payments up to $190 million plus royalties on product sales. Further terms are not being disclosed.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.